On Oct. 6, 2026, BD (Becton, Dickinson and Company), one of the world’s leading medical technology companies and the nation’s largest manufacturer of essential medical consumables, announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day.  

Through this partnership, BD intends to:  

• Invest $19 billion in the U.S. over several years, including capital, operational and supply chain investments.
• Direct $3 billion of the overall investment toward U.S. manufacturing expansion focused on strategic production sites across the country.
• Expand end-to-end U.S. production by approximately 5 billion essential medical consumables annually, raising BD’s share of domestically supplied essential medical consumables to roughly 80 percent.
• Manufacture 100 percent of BD needles used in America domestically using American-made steel.

The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD’s achievement of agreed milestones. This provides greater long-term certainty for manufacturing and supply chain planning as BD advances investments in U.S. production, innovation and healthcare infrastructure. Because the final tariff rates, product scope and effective timing have not yet been determined, BD is not currently quantifying the financial impact of the agreement. The company expects to provide additional information when the Section 232 tariffs are finalized.   

BD’s U.S. manufacturing network is deeply rooted in communities across the country, including Columbus and Broken Bow, NE; Canaan, CT; Añasco, PR; Sandy, UT; El Paso, TX; Covington, GA; and Sumter, SC. For generations, BD has helped meet critical healthcare needs through innovation, manufacturing excellence and the reliable supply of essential medical technologies. From developing the first disposable syringe that helped advance the fight against polio to delivering more than two billion additional devices during the recent pandemic, BD has worked alongside healthcare providers and governments to respond to evolving patient and public health needs.